Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 92

Results For "Vice-President"

933 News Found

QIAGEN and GT Molecular collaborate to detect SARS-CoV-2 in wastewater
Drug Approval | August 11, 2021

QIAGEN and GT Molecular collaborate to detect SARS-CoV-2 in wastewater

Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases


GSK files application for MMR vaccine in the US
News | August 11, 2021

GSK files application for MMR vaccine in the US

If approved it will bring a second source of MMR vaccine to the US market


GW Pharmaceuticals receives approval for Epidyolex to treat seizures
Drug Approval | August 11, 2021

GW Pharmaceuticals receives approval for Epidyolex to treat seizures

TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines


Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings
Biotech | August 10, 2021

Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings

A veteran in cell therapy and oncology commercialisation


QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
Drug Approval | August 10, 2021

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab


Kite and Appia Bio collaborate to research and develop Allogeneic cell therapies for cancer
Biotech | August 10, 2021

Kite and Appia Bio collaborate to research and develop Allogeneic cell therapies for cancer

It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies


FDA approves Nexviazyme for late-onset Pompe disease
Drug Approval | August 09, 2021

FDA approves Nexviazyme for late-onset Pompe disease

Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells


Abbott receives FDA clearance for its imaging tech using AI
Digitisation | August 04, 2021

Abbott receives FDA clearance for its imaging tech using AI

Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -


Abbott's Freestyle Libre 2 Ios App Cleared In U.S
Drug Approval | August 03, 2021

Abbott's Freestyle Libre 2 Ios App Cleared In U.S

FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms


Triastek closes US $50 Mn Series B Financing
News | July 01, 2021

Triastek closes US $50 Mn Series B Financing

In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline